SCHEMBL6067993

SCHEMBL6067993

Cc1ccc(-c2cc(O)cc(O)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.67
ABCB1 P08183 4/20 0.67
BCR P11274 4/20 0.67
NPC1 O15118 1/20 0.58
TP53 P04637 1/20 0.58
MAPK1 P28482 1/20 0.58
CASP3 P42574 1/20 0.58
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
ACHE P22303 1/20 0.52
ESR1 P03372 2/20 0.50
HDAC1 Q13547 1/20 0.47
NQO1 P15559 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MCL1 Q07820 1/20 0.45
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11783049 0.95 ABL1 (0.59) ABL1ABCB1BCRNPC1TP53
SCHEMBL18612841 0.86 EGFR (0.60) ABL1ABCB1BCRNPC1TP53
SCHEMBL2090372 0.86 ABL1 (0.88) ABL1ABCB1BCRNPC1TP53
SCHEMBL12755199 0.84 ESR1 (0.74) ABL1ABCB1BCRACHEESR1
SCHEMBL18675344 0.83 ABL1 (0.82) ABL1ABCB1BCRNPC1TP53
SCHEMBL11362260 0.80 ACHE (0.81) ABL1ABCB1BCRNPC1MAPK1
SCHEMBL894975 0.80 ACHE (0.81) ABL1ABCB1BCRNPC1MAPK1
SCHEMBL379088 0.80 ABL1 (1.00) ABL1ABCB1BCRNPC1TP53
SCHEMBL22555726 0.80 ABL1 (0.68) ABL1ABCB1BCRNPC1TP53
SCHEMBL19288252 0.80 ACHE (0.57) NPC1RAB9AACHEESR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-20240239931-A1 FLUORINATED RESORCINOL AND HYDROQUINONE ANALOGS AS CURING AGENTS FOR FLUOROELASTOMERS CHEMOURS COMPANY FC, LLC, THE 2024-07-18 US disclosed
WO-2009067697-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2009-05-28 WO disclosed
US-20080184881-A1 MESH-ADJUSTABLE MOLECULAR SIEVE MIAMI UNIVERSITY (US) 2008-08-07 US disclosed
US-7125428-B2 1,3-Dihydroxybenzene derivatives and colorants containing said compounds WELLA AG (DE) 2006-10-24 US disclosed
EP-1392673-A2 1,3-DIHYDROXYBENZENE DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS Wella Aktiengesellschaft (DE) 2004-03-03 EP disclosed
US-20040016063-A1 1,3-Dihydroxybenzene derivatives and colorants containing said compounds HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) 2004-01-29 US disclosed
WO-2002096901-A2 1,3-DIHYDROXYBENZENE DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS WELLA AKTIENGESELLSCHAFT (DE) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040016063-A1 1,3-Dihydroxybenzene derivatives and colorants containing said compounds KRT18, DSP, COL1A1 ABL1 2506/4885ABCB1 860/4885BCR 1896/4885
US-20080184881-A1 MESH-ADJUSTABLE MOLECULAR SIEVE TRPA1, TRPM4, TRPV4 ABL1 3499/4885ABCB1 690/4885BCR 2713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.